KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 93 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $12,241,000 | -21.3% | 830,472 | -29.3% | 0.27% | -16.0% |
| Q4 2021 | $15,547,000 | -58.8% | 1,175,131 | -45.7% | 0.33% | -55.8% |
| Q3 2021 | $37,754,000 | -27.2% | 2,163,554 | 0.0% | 0.74% | -20.0% |
| Q2 2021 | $51,839,000 | +97.8% | 2,163,554 | +112.1% | 0.92% | +67.2% |
| Q1 2021 | $26,204,000 | +153.6% | 1,020,005 | +14.5% | 0.55% | +30.9% |
| Q3 2019 | $10,332,000 | -61.7% | 890,668 | -26.9% | 0.42% | -56.6% |
| Q2 2019 | $26,971,000 | +45.0% | 1,217,668 | +87.3% | 0.97% | +35.9% |
| Q1 2019 | $18,603,000 | +44.9% | 650,000 | 0.0% | 0.71% | +38.7% |
| Q4 2018 | $12,838,000 | -10.7% | 650,000 | 0.0% | 0.51% | -0.2% |
| Q3 2018 | $14,372,000 | – | 650,000 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |